The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease – FierceBiotech
- Hansa Biopharma Gets up to 350M to Make Gene Therapy Work in Resistant… – Labiotech.eu
- FDA Grants Orphan Drug Designation to Neurogene’s Gene Therapy for the Treatment of CLN5 Batten Disease – BioSpace
- Tiny mineral particles are better vehicles for promising gene therapy – ScienceBlog.com
- The Wilderness of Rare Genetic Diseases and the Parents Navigating It – The New York Times
- avast warning for phishing
- the concept of race has no genetic or scientific basis” and that “race is a social concept not a scientific one” (Witt 2010)
- Nanomedicine-Nanotechnology Biology and Medicine
- what happened to jackson avery on greys
- broadcast schedule
- greys anatomy jackson child
- harris silver md
- heroes season 1 claires immortality
- pros and cons of human activity on plants and animals
- higher ed mcat
|Search Immortality Topics:|
Category Archives: Nano Medicine
A scientific paper co-authored by the former president of the European Research Council has been retracted after duplicated images were detected in the research.
In anannouncementon 26 June, the journalScience Advancessaid that it had retracted a paper published in April on what appeared to be a potentially game-changing method of delivering diabetes drugs orally, rather than through injections.
The paper,titledMolecular targeting of FATP4 transporter for oral delivery of therapeutic peptide, seemed to offerhopethat drugs for other diseases, such as rheumatoid arthritis and other autoimmune diseases, could eventually be given as a pill.
The results, which showed how mice were able to absorb the drug effectively in their stomachs, appeared to clear the way for clinical trials on humans, the studys corresponding author Haifa Shen, professor of nanomedicine at the Houston Methodist Research Institute, told theMedical Xpresswebsite in April.
Among the papers authors all of whom were associated with the Houston institute at the time of publication was Mauro Ferrari, who was head of the European Research Council for three months earlier this year before quitting in April over what he saw as the European Unions response to the coronavirus pandemic.
Science Advances, the only open-access journal in theSciencefamily of journals, says that it retracted the paper after readers identified duplicated image regions in multiple figure panels.
Alerted to these concerns, the corresponding authors institution performed a review of the supporting data and research records and determined that the research was not performed according to expected standards and was not reliable, it says.
Therefore, we wish to retract this research article promptly, it continues, adding that it apologise[s] that these errors were not discovered before the manuscript was published.
The journal said that all the authors had agreed that the paper should be retracted, except one its lead author Zhenhua Hu, who did not respond to his co-authors communications.
Times Higher Education contacted Professor Shen, who conducted the review of readers concerns, for comment.
Following Professor Ferraris resignation from the ERC, senior officials said that they had asked him to resign over a litany of failings that predated the pandemic, including spending too much time in the US and a complete lack of appreciation for the raison dtre of the ERC, namely bottom-up research suggested by academics, rather than top-down efforts dictated from above.
17.8 Commentary on Hurdles in Clinical Translation of Various Nanotechnology Products
Research regarding nanoconstructs development in the cancer treatment field has witnessed a noticeable increase after discovery of the EPR effect. However, the number of anticancer drugs that actually reached the market was considered extremely low, as out of 200,000 anticancer drugs only 15 made it by 2017 (Greish et al., 2018). The reasons why most of the nanomedicines cannot even reach the market are the hardship or inability to maintain detailed characterization of these products, unsuccessful manufacturing on large scales, and issues in their safety and efficacy. These hurdles require many developmental processes to overcome them including a precise understanding of every component and all the possible interactions between them, determination of key characteristics to understand in which possible ways they affect performance, and the extent of it. If key characteristics can be replicated under manufacturing conditions (scaling up), the efficacy of targeting at the site of action and their stability and sterility can be enhanced and/or assessed (Desai, 2012). The majority of these hurdles are summarized in Table 17.5 (Tinkle et al., 2014).
Table 17.5. Major Hurdles That Face the Commercialization of Nanomedicine
Lack of standard nano nomenclature: imprecise definition for nanomedicines
Currently used compounds/components for nanodrug synthesis often pose problems for large-scale good manufacturing (cGMP) production
Lack of precise control over nanoparticle manufacturing parameters and control assays
Lack of quality control: issues pertaining to separation of undesired nanostructures (byproducts, catalysts, starting materials) during manufacturing
Reproducibility issues: control of particle size distribution and mass
Scalability complexities: enhancing the production rate to increase yield
High fabrication costs
Lack of rational preclinical characterization strategies via multiple techniques
Biocompatibility, biodistribution and toxicity issues: lack of knowledge regarding the interaction between nanoparticles and biosurfaces/tissues
Consumer confidence: the publics general reluctance to embrace innovative medical technologies without clearer safety or regulatory guidelines
The relative scarcity of venture funds
Ethical issues and societal issues are hyped up by the media
Big Pharmas continued reluctance to seriously invest in nanomedicine
Patent review delays, patent thickets, and issuance of invalid patents by the US Patent and Trademark Office
Regulatory uncertainty and confusion due to baby steps undertaken by US Food and Drug Administration: a lack of clear regulatory/safety guidelines
One of the major concerns related to NPs is their potential incompatibility and toxicity. Studies showed that inhaling NPs can cause pulmonary inflammation as well as inducing endothelial dysfunction that might lead to further complications in the cardiovascular system. A study for evaluation of iron oxide toxicity showed that monocyte-mediated dissolution and phagocytosis of the NPs have caused severe endothelial toxicity by initiating oxidative stress. Nanomaterials used in oral DDS have been shown to accumulate in hepatic cells, which might induce the immune response and eventually cause permanent damage to the liver. The accumulation of NPs in cells has been found to cause cancer by transforming cells into the tumorous state (Jain et al., 2018; Riehemann et al., 2009). Thus, handling these nanosystems requires special equipment and caution, which increases the cost of the production process and requires further investigations of the safety of nanomaterials to have a better understanding and optimize safety during manufacturing (Hammed et al., 2016). Production of NPs in the laboratory often requires complex, multistep synthesis processes to yield the nanomaterials with the required properties. Aside from the complexity of the process, controlling conditions such as temperature and concentrations precisely is significant to achieve homogeneity of NPs in terms of desired characteristics. However, retaining temperature and concentration in large systems is harder to achieve resulting in NPs with different characteristics (Gomez et al., 2014).
NPs tend to aggregate forming clusters with several microns in size. Aggregation of NPs alters their characteristics such as reactivity, transport, toxicity, and risk in the environment. Dissolution reduces when aggregation occurs due to the decrease in available surface area that will eventually reduce the activity of NPs. For example, dechlorination rate of CT (carbon tetrachloride) by magnetite NPs has shown to decrease when aggregation of the NPs increases resulting in an inverse relationship between dechlorination rate of carbon tetrachloride and aggregation of magnetite NPs (Hotze et al., 2010; Hou and Jafvert, 2009).
All these requirements are extremely important because the majority of the nanomedicines have failed to reach the commercialization step even though their efficacy in animal models was considerably high. Due consideration must be given regarding the several difficulties such as their low targeting, low safety, low efficacy, heterogeneity of disease between individuals, inability to scale-up successfully, and unavailability in determining a convenient characterization methods (Agrahari and Agrahari, 2018; Hare et al., 2017; Kaur et al., 2014). These hurdles that face the research process of accelerated translation are summarized in Fig. 17.8 (Satalkar et al., 2016).
Figure 17.8. Major issues that face accelerated translation process of nanoparticles.
Therefore, more understanding in all aspects of nanomedicine production, characterization, and clinical processes must be fulfilled to control and improve the development processes, and increase the efficacy of the translational methods. Other significant hurdles hindering clinical translation are the insignificant incentives regarding technology transfer, as well as socioeconomic uncertainties along with the safety problems faced. In the majority of cases, consideration of commercialization aspects in early stages of development is hardly even considered thus eliminating the market-oriented development (Rsslein et al., 2017).
Nanomedicines face tough, challenging concerns when it comes to determining the applicable analytical tests in terms of chemical, physical, or biological characterization. This is mainly achieved due to their complex nature in comparison with other pharmaceutical products. Hence, there is a need for more complex and advanced levels of testing to ensure a full accurate characterization of nanomedicine products. Quantification of each component of nanomedicine is considered essential alongside the identification and evaluation of interactions between them. For more possibility in achieving successful manufacturing processes with reproducibility, these products should be investigated and understood more during the early developmental stages to identify their key characteristics. The challenges for nanomedicine during scale-up and manufacturing are considered relatively unique because other pharmaceutical manufacturing processes systems are not three-dimensional multicomponent in nature on the nanometer scale. Therefore, a certain series of obstacles in the scale-up process is required. To reach the desired safety, pharmacokinetic and pharmacodynamic parameters to produce the therapeutic effect are needed. These are further determined by the proper selections of the essential components, determination of the critical manufacturing steps, and key characteristics identification. Several methods of orthogonal analysis are essential for in-process quality controls of nanoparticle products and any deviations from key parameters could result in a significant negative impact on both the safety and efficacy of nanomedicines (Desai, 2012).
Each step in the manufacturing process of NPs must be understood extensively with the need of experienced technicians. The development process also requires more enhancements in both complexity and cost. Inadequate data regarding scaling-up processes of nanomedicine products is a major concern in the commercialization step as there are only a few reports supporting scaling-up developments. Many formulation methods have been developed for manufacturing nanomedicine products. The most common methods are nanoprecipitation and emulsion-based approaches. Generally, formulations are prepared either by precipitating the dissolved molecules (bottom-up method) or by reducing the size of larger drug particles (top-down method). Removal of the solvent in the bottom-up method is not an easy process and it cannot be controlled well either, thus explaining why this method is less often applied in industrial manufacturing (Agrahari and Agrahari, 2018; Vauthier and Bouchemal, 2009). Investments in innovative projects face several issues with the major one being the knowledge that should be obtained from the innovation. Its confidentiality is easily breached when a company uses that knowledge as it cannot prevent other companies from using it. Thus, investors are not attracted to this type of project because the total return on the investment cannot be easily appropriated (Morigi et al., 2012).
The complexities in formulating nanoproducts on large scales are due to the inability of optimization of formulation processes and achieving reproducibility. Whereas formulation steps including size reduction, homogenization, centrifugation, sonication, solvent evaporation, lyophilization, extrusion, and sterilization can be easily optimized on small-scales, its still a challenging process on large-scales. Accordingly, variations between batches cannot be controlled sufficiently thereby limiting the possibility of nanomedicine to get through commercial translation (Anselmo et al., 2017; Desai, 2012).
Another problem is that even slight changes in either the formulation or the manufacturing process can have a significant effect on the nanomedicine physiochemical properties (crystallinity, size, surface charge, release profile), which will ultimately influence the therapeutic outcome. Most of the pharmaceutical industrial facilities cannot manufacture nanomedicines because of the lack of the right equipment for the process. As nanomedicine manufacturing usually involves the use of organic solvents, the ability to correctly process and handle nanoproducts is crucial to control their safety and sterility (Anselmo et al., 2017; Desai, 2012; Kaur et al., 2014). These steps require an expensive and complicated equipment, well-trained staff, and precise control to get the required product in the right quality (Desai, 2012; Kaur et al., 2014; Ragelle et al., 2017).
To date, only 58 nanoformulations are approved based on their clinical efficacy but only a quarter of them are meant for cancer treatment. Majority of the nanoformulations could not even be reproduced successfully due to several factors including the study design, overall analysis, protocols, data collection, and the quality and purity of materials used. Besides, the poor establishment of the correlation and prediction of safety and efficacy of the nanomedicine on patients hinders the successful DDS. Targeting and drug accumulation of anticancer drugs in the site of action is considered relatively poor in mouse models. Many nanoformulations were faced with failure in different clinical trial phases. Some of them got approved but then withdrawn from the market such as peginesatide. Unfortunately, the increased failures will most probably affect the development movement in the pharmaceutical industry (Greish et al., 2018).
At the present time, regulatory agencies such as the FDA and EMEA are examining every new nanomedicine on a product-by-product basis. They are considered a unique category due to the fact that there are no true standards in their examination process (Desai, 2012). Two of the major regulatory issues that emerged at the start of nanomedicine is the lack of scientific experts in the FDA and the difficulty in classifying the product (Morigi et al., 2012). The unique characteristics of nanomedicines are directly related to their regulation hurdles, which is the same as other pharmaceutical systems such as liposomes and polymeric systems (Sainz et al., 2015).
Researchers keep investigating nanomedicines when attached to prodrugs, drugs, tracking entities, and targeting molecules. Development of robust methods and assays in quality control of nanomedicines are required for more effective monitoring and characterizations. Also, estimation of their overall performance in releasing drugs, binding to proteins, and the specificity in cellular uptake must be considered (Sainz et al., 2015; Tinkle et al., 2014).
Nanomedicine products are both complex and diverse requiring explanation of challenges to have a clear definition and an effective regulation. The lack of regulatory guidelines for these products hinders their clinical potential. Drug regulatory authorities must keep up with the rapid pace of the knowledge and technological development as they play a major role translating nanomedicines towards the market. The European Medicines Agency (EMEA) and the FDA have different requirements in evaluating new nanomedicines as well as different definitions regarding nanomedicine. Agreeing on specific regulatory procedures internationally is very important to ease the translational researches of nanomedicines. Also, better long-term monitoring of toxicity should be achieved by prolonging postmarketing surveillance especially for a patient with chronic diseases (Sainz et al., 2015; Tinkle et al., 2014).
Nanomedicines just like any other pharmaceutical formulations must offer higher value to patients to become commercially successful, and have better efficacy and safety. New nanomedicine products follow the same steps in clinical trials as other drugs. It starts with preclinical tests, then be submitted to get the IND (investigational new drug) approval and following that it enters the three stages of clinical trials, one after another to evaluate safety and efficacy of the new drug (Agrahari and Agrahari, 2018).
In recent years, toxicities caused by nanomedicines have drawn attention and been recognized to be unique to nanoparticulate systems. Hence, a minimum set of measurements for the nanoparticle like surface charge, size, and solubility are monitored so as to predict the possible toxicity of NPs. Besides, NPs can stimulate the immune system by acting as an antigen. Immunogenicity is mainly affected by the size of the nanoparticle, its surface characteristics, hydrophobicity, charge, and solubility. Hematologic safety concerns have also been observed such as hemolysis and thrombogenicity (Desai, 2012).
In vivo and in vitro studies provide the proper characterization of the interactions between the product and the biological system. The problem is that the data attained from current toxicity tests are not from clinical trials and it cannot always be extrapolated to humans. Monolayers of cell cultures are currently used to characterize immunogenicity, drug release, cellular uptake, and toxicity. However, the cellular uptake process of nanoformulations is majorly influenced by physicochemical characteristics. Thus, 3D cell systems will probably provide better outcomes (Gupta et al., 2016). More caution should be given when handling any nanosized powder due to the ability of such particles to penetrate the skin and because it can also show pulmonary toxicity (Agrahari and Hiremath, 2017; Nel et al., 2006).
Nanomedicine - an overview | ScienceDirect Topics
Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type…
The Healthcare Nanotechnology (Nanomedicine) Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Healthcare Nanotechnology (Nanomedicine) market report covers the worldwide top manufacturers like (Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Healthcare Nanotechnology (Nanomedicine) market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Healthcare Nanotechnology (Nanomedicine) Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.
Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Healthcare Nanotechnology (Nanomedicine)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2041239
Healthcare Nanotechnology (Nanomedicine) Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Healthcare Nanotechnology (Nanomedicine) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Healthcare Nanotechnology (Nanomedicine) Market Background, 7) Healthcare Nanotechnology (Nanomedicine) industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Healthcare Nanotechnology (Nanomedicine) Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.
Scope of Healthcare Nanotechnology (Nanomedicine) Market:It is defined as the study of controlling, manipulating and creating systems based on their atomic or molecular specifications. As stated by the US National Science and Technology Council, the essence of nanotechnology is the ability to manipulate matters at atomic, molecular and supra-molecular levels for creation of newer structures and devices. Generally, this science deals with structures sized between 1 to 100 nanometer (nm) in at least one dimension and involves in modulation and fabrication of nanomaterials and nanodevices.
Nanotechnology is becoming a crucial driving force behind innovation in medicine and healthcare, with a range of advances including nanoscale therapeutics, biosensors, implantable devices, drug delivery systems, and imaging technologies.
The classification of Healthcare Nanotechnology includes Nanomedicine, Nano Medical Devices, Nano Diagnosis and Other product. And the sales proportion of Nanomedicine in 2017 is about 86.5%, and the proportion is in increasing trend from 2013 to 2017.
On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.
Anticancer CNS Product Anti-infective Other
On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.
Nanomedicine Nano Medical Devices Nano Diagnosis Other
Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2041239
Geographically, the report includes the research on production, consumption, revenue, Healthcare Nanotechnology (Nanomedicine) market share and growth rate, and forecast (2020-2026) of the following regions:
Important Healthcare Nanotechnology (Nanomedicine) Market Data Available In This Report:
Strategic Recommendations, Forecast Growth Areasof the Healthcare Nanotechnology (Nanomedicine) Market.
Challengesfor the New Entrants,TrendsMarketDrivers.
Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.
This Report Discusses the Healthcare Nanotechnology (Nanomedicine) MarketSummary; MarketScopeGives A BriefOutlineof theHealthcare Nanotechnology (Nanomedicine) Market.
Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.
Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Healthcare Nanotechnology (Nanomedicine) Market.
Healthcare Nanotechnology (Nanomedicine) Market ShareYear-Over-Year Growthof Key Players in Promising Regions.
What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Healthcare Nanotechnology (Nanomedicine) market?
To Get Discount of Healthcare Nanotechnology (Nanomedicine) Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2041239
ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]
Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/
The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine.
Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.
Nanomedicine: NBM journal publishes articles on artificial cells, regenerative medicine, gene therapy, infectious disease, nanotechnology, nanobiotechnology, nanomedicine, stem cell and tissue engineering.
Sub-categories include synthesis, bioavailability, and biodistribution of nanomedicines; delivery, pharmacodynamics, and pharmacokinetics of nanomedicines; imaging; diagnostics; improved therapeutics; innovative biomaterials; interactions of nanomaterials with cells, tissues, and living organisms; public health; toxicology; theranostics; point of care monitoring; nutrition; nanomedical devices; prosthetics; biomimetics; and bioinformatics.
Article formats include Rapid Communications, Original Articles, Reviews, Perspectives, Technical and Commercialization Notes, and Letters to the Editor. We invite authors to submit original manuscripts in these categories.
Originally posted here:
Nanomedicine: Nanotechnology, Biology and Medicine ...
Developing and Manufacturing Novel RNAi drug Candidates Using Precision NanoSystems' NxGen Platform
GAITHERSBURG, MD andVANCOUVER, BC, June 17, 2020 /PRNewswire/ - Sirnaomics Inc. (Sirnaomics) and Precision NanoSystems Inc. (PNI) jointly announced a partnership on the development and manufacture of Sirnaomics polypeptide nanoparticle-based RNAi therapeutic product. This strategic joint effort includes the execution of a NanoAssemblr platform license and supply agreement, plus successful production of multiple batches of Sirnaomics drug product candidates, STP705 and STP707, for ongoing IND enabling safety and toxicity studies, as well as several clinical studies.
Sirnaomics is a clinical stage biopharmaceutical company specialized in RNAi-based therapeutics for addressing the unmet needs in treatment of cancers and fibrosis diseases. The company has developed proprietary polypeptide nanoparticle carriers for efficient siRNA delivery, to advance an enriched drug product pipeline. Sirnaomics' lead product candidate, STP705, is an siRNA (small interfering RNA) therapeutic which takes advantage of a dual-targeted inhibitory property together with a polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA, including treatments of Cholangiocarcinoma, Non-Melanoma skin cancer and Hypertrophic Scar. STP705 has also received Orphan Drug Designation for treatment of Cholangiocarcinoma, Primary Sclerosing Cholangitis and Hepatocellular Carcinoma. A recent interim analysis report of a phase IIa clinical study on STP705 for treatment of Squamous Cell Carcinoma in situ indicated the topline therapeutic results with complete histological clearance tumor cell on treated sites. Using the same dual targets design, Sirnaomics has further developed STP707, a systemic formulation with broader application potential.
Sirnaomics' founder, president and CEO, Dr. Patrick Lu said, "As the leader in RNAi therapeutics specialized in polypeptide nanoparticle formulation, we are so excited to see the further advancement of our process development and large scale product manufacturing, using PNI's NxGen microfluidic technology. In working with PNI's team and the NanoAssemblr platform, we were able to establish a robust manufacturing process from a nominated drug candidate to GMP manufacturing in just a few months, greatly accelerating our drug development process". Sirnaomics is currently using these batches produced with NxGen for non-human primate safety toxicity studies and clinical studies."
PNI is a global leader in technology solutions to enable the development and manufacture of new nanomedicines in the areas of vaccines, cell therapies and gene therapies for the treatment of oncology, infectious diseases, and rare diseases. With the NanoAssemblr suite of products, PNI provides solutions across the drug development process for clients to develop and seamlessly scale their drug programs. Dr. James Taylor, co-founder and CEO of PNI said, "We are pleased to support Sirnaomics, an innovative RNAi therapeutics company, with our NanoAssemblr platform and Clinical Solutions Team that helped take their drug program to a successful GMP batch manufacture. We believe the NanoAssemblr microfluidic technology enables exquisite control over the particle size, charge and encapsulation efficiency which was important for the performance of Sirnaomics' drug product candidates." PNI's NanoAssemblr platform, with over 400 systems placed worldwide, is designed to enable drug developers to rapidly progress from R&D to industrial-scale nanomedicine manufacture.
About SirnaomicsSirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at http://www.sirnaomics.com.
About Precision NanoSystems Inc.Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information visithttp://www.precisionnanosystems.com.
SOURCE Precision Nanosystems
Originally posted here:
Sirnaomics and Precision NanoSystems Have Formed a Partnership - PRNewswire
Global Healthcare Nanotechnology (Nanomedicine) Market 2020 with (Covid-19) Impact Analysis: Business Outlook, Future Growth and Regional Forecasts…
Researchstore.biz, after comprehensive analysis, has introduced a new research study titled Global Healthcare Nanotechnology (Nanomedicine) Market 2020 by Company, Type and Application, Forecast to 2025, which highlights developments, industry challenges that competitors are facing along with gaps and opportunities available in the market. The report includes the data about the product in the market, marketing patterns pursued by the business, top players, up and coming trends. The report provides an assessment of the market and contains important insights, historical data, and industry-validated market data. The report covers market evolution, overview, value chain, trade scenario, market size, market segmentation, and competitive scenario. Information as per the market segments such as geographies, products, technologies, applications is given in the report.
The report presents insightful analyses of the market and has a comprehensive understanding of the global Healthcare Nanotechnology (Nanomedicine) market industry analysis and forecast 2020-2025 and its commercial landscape. Critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics. The complete value chain and downstream and upstream essentials are scrutinized in this report. It additionally seriously explored the global Healthcare Nanotechnology (Nanomedicine) market development pattern based on regional order. Marketing strategies and different channels have been listed here.
DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/47548
NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.
Key companies profiled in the market report are Amgen, Merck & Co, UCB, Teva Pharmaceuticals, Sanofi, Abbott, Stryker, Celgene, Roche, Biogen, SmitH& Nephew, Takeda, Gilead Sciences, Endo International, Leadiant Biosciences, Johnson & Johnson, Pfizer, Ipsen, Kyowa Hakko Kirin, 3M Company, and more in terms of company basic information, product introduction, application, specification, production, revenue, price and gross margin (2015-2020), etc.
Differentiation of the market based on types of product: Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other
Differentiation of the market based on types of its application: Anticancer, CNS Product, Anti-infective, Other
Geographically, this report studies the top producers and consumers in these key regions: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa). Here each geographic segment of the Healthcare Nanotechnology (Nanomedicine) market has been independently investigated along with pricing, distribution, and demand data for geographic market.
What Insights Does The Healthcare Nanotechnology (Nanomedicine) Market Report Provide To The Readers?
Moreover, the report focuses on the key global Healthcare Nanotechnology (Nanomedicine) market manufacturers and aims to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis, and development plans in the next few years. Moreover, for forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end-user trends, and production capacity are taken into consideration. It also covers a short outline of the dealers, distributors, and suppliers.
Key Developments In The Market: This segment of the Healthcare Nanotechnology (Nanomedicine) market report combines the major developments of the market that contains confirmations, composed endeavors, R&D, joint endeavors, and the relationship of driving members working in the market. The anticipated growth rate expected to be recorded by each region over the estimated years has been given within the research report.
Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.
Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.
Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz